Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Approvals Action
Bayer's oral pan-tumour ticked

Posted 14 September 2020 

The TGA has provisionally approved Bayer's Vitrakvi, marking the first pan-tumour medicine for childhood and adult NTRK cancers in Australia.

Vitrakvi is an oral tropomyosin receptor kinase (TRK) inhibitor approved for use in patients of any age with advanced solid tumours with NTRK gene fusion regardless of the tumour's location.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
Live updates on frontrunners, local trials and deals
Approvals Action
Six pharmas add generics
Most copy PBS listed drugs
Top of the Hill
If only for a 2020 time machine
What would you do if you could start this year again?